

The simplest test yet to detect Chlamydia



With the growing awareness of infections with Chlamydia trachomatis, laboratories are being asked to perform more and more tests.

CLEARVIEW CHLAMYDIA
substantially eases your workload.

Following sample extraction, it takes just one step to get a reliable result – just add the extract and in only 15 minutes the results are revealed.

CLEARVIEW CHLAMYDIA
needs little “hands-on” manipulation, allowing a large number of tests to be performed daily. It's so simple – no specialised equipment or training is required. Any member of staff can do the test, simply and accurately.


CLEARVIEW CHLAMYDIA
detects the presence of chlamydia with 98.8% specificity and 87.0% sensitivity.*

CLEARVIEW CHLAMYDIA
is the simplest and most convenient test to detect this important pathogen.


CLEARVIEW

FROM UNIPATH

Unipath Limited, Bedford MK41 0QG, England. Clearview and the diamonds device are trademarks of Unipath Limited.



Non-specialists overwhelmed by too many systematic descriptions of individual disease will welcome the new approach of *ABC of Dermatology*. Here the history, clinical appearance, and pathology of a few common key conditions are discussed and then as a basis for comparison with other skin diseases. Also dealing in detail with allergic reactions, autoimmunity, acne, and infections, this handbook is **fully illustrated in colour**, providing a clear guide to assessment and treatment as well as an understanding of the histological changes underlying the clinical presentations.

Price: Inland £11.95; Abroad £13.50. BMA members: Inland £10.95; Abroad £12.50 including postage, by air abroad.

Please enclose payment with order or send us full details of your ACCESS, AMERICAN EXPRESS or VISA credit card.

ORDER FROM: BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE
or any leading medical bookseller

BMJ

Published weekly
Annual Subscription
Inland £110.00; Abroad £134.00

Associated Specialist Journals

Annals of the Rheumatic Diseases

Monthly (+ two extra supplements). Annual Subscription Inland £138.00; Abroad £151.00

Archives of Disease in Childhood

Monthly (+ four Fetal and Neonatal editions). Annual Subscription Inland £127.00; Abroad £140.00

British Heart Journal

Monthly. Annual Subscription Inland £126.00; Abroad £136.00

Combined Annual Subscription to British Heart Journal and

Cardiovascular Research Inland £238.00; Abroad £255.00

Cardiovascular Research

Monthly. Annual Subscription Inland £153.00; Abroad £167.00

British Journal of Industrial Medicine

Monthly. Annual Subscription Inland £98.00; Abroad £103.00

British Journal of Ophthalmology

Monthly. Annual Subscription Inland £126.00; Abroad £138.00

Genitourinary Medicine

Six issues. Annual Subscription Inland £95.00; Abroad £101.00

Gut

Monthly. Annual Subscription Inland £121.00; Abroad £130.00

Journal of Clinical Pathology

Monthly. Annual Subscription Inland £137.00; Abroad £146.00

Journal of Epidemiology and Community Health

Quarterly. Annual Subscription Inland £68.00; Abroad £70.00

Journal of Medical Ethics

Quarterly. Annual Subscription Inland £49.00; Abroad £64.00

Journal of Medical Genetics

Monthly. Annual Subscription Inland £126.00; Abroad £134.00

Journal of Neurology, Neurosurgery and Psychiatry

Monthly. Annual Subscription Inland £128.00; Abroad £138.00

Thorax

Monthly. Annual Subscription Inland £124.00; Abroad £132.00

Professional and Scientific Publications

BDA News

19 issues a year. Annual Subscription Inland £25.00; Abroad £30.00

BMA News Review

Monthly. Annual Subscription Inland £33.00; Abroad £37.00

British Dental Journal

22 issues a year. Annual Subscription Inland £127.00; Abroad £160.00

British Journal of Anaesthesia

Monthly. Annual Subscription Inland £100.00; Abroad £107.00

Current Work in the History of Medicine

Quarterly. Annual Subscription Inland £23.00; Abroad £28.00

Eye

Six issues. Annual Subscription Inland £128.00; Abroad £149.00

Health Visitor

Monthly. Annual Subscription Inland £43.00; Abroad £48.00

Medical History (including Annual Supplement)

Quarterly. Annual Subscription Inland £67.00; Abroad £76.00

Sample copies available
on request.

All subscription rates
include postage, by air
speeded despatch abroad.

Subscription rates
apply to 1991

BMJ BRITISH MEDICAL JOURNAL, BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND

Prescribing information

Indications and dosage: Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: at least 100mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Vaginal candidiasis: single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. **Administration:** Diflucan may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. **Contra-indications:** Hypersensitivity to fluconazole or related triazoles, pregnancy and women of childbearing potential unless adequate contraception is employed.

Warnings: Lactation: Not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. **Drug interactions:** Monitor patients on concurrent anticoagulants, oral sulphonylureas, phenytoin or rifampicin. **Side effects:** Nausea, abdominal discomfort, diarrhoea and flatulence. **Package Quantities and basic NHS Cost:** 50mg capsule, calendar pack of 7, £16.61 (PL 57/0289); 200mg capsule, calendar pack of 7, £66.42 (PL 57/0317); 150mg capsule, pack of 1, £7.12 (PL 57/0290); Bottles of 25ml and 100ml containing Diflucan 2mg/ml intravenous infusion - 25ml (50mg) bottle, £7.32; 100ml (200mg) bottle, £29.28 (PL 57/0315). Hospital prices are available on request. **References:** 1-4 Data on file, Pfizer Ltd. Further information on request.



Pfizer Limited, Sandwich, Kent

Antifungal therapy that's severe on the infection, not on the patient.

Diflucan Oral/I.V. is highly effective, well tolerated therapy with a convenient, once a day dosage and administration.

Overall clinical responses in deep-seated fungal infections are impressive: 87% in systemic candidiasis¹, 96% in mucosal candidiasis² and 62% in cryptococcal meningitis.³ Tolerability is similarly impressive with adverse effects comparable to placebo.⁴

Diflucan Oral/I.V. Treating invasive fungal infection with an iron fist and patients with a velvet glove.

Diflucan ORAL/I.V.
fluconazole *Trade Mark

Counters invasive fungal infection